Aspen Prospectus Offers 9,375,000 Shares at Expected Price of $15 to $17
Key Facts
Aspen Neuroscience offered 9,375,000 shares of its common stock for sale at an expected initial price of $15 to $17 per share in an amended prospectus filed with the U.S. Securities and Exchange Commission on October 26, 2026. The company said in the prospectus: "We expect the initial public offering price to be between $15 and $17 per share." The document does not establish that the final price was set at $15, nor does it establish that the offering process was completed or that share trading began. The figure therefore remains an indicative range in a preliminary document, not an announced final price. The company has applied to list the shares on the Nasdaq Global Select Market under the ticker ASPE, with the offering still subject to listing approval.
The prospectus allows the underwriters to purchase up to 1,406,250 additional shares within 30 days of the offering date. This option gives the underwriters the ability to increase the number of shares offered within the specified limit, but does not mean the additional shares have been purchased. The number of shares in the base offering is also separate from the maximum covered by the option. According to the company’s disclosure, the offering remains contingent on Nasdaq listing approval. The prospectus made available does not state a final price or a date for trading to begin.
Aspen’s business centers on sasineprocel, an experimental therapeutic candidate that the company describes as a single-dose cell therapy based on autologous induced pluripotent stem cells, meaning cells derived from the patient. The candidate is being evaluated as a treatment for Parkinson’s disease, and no company product had received marketing approval as of the disclosure date. Aspen said it had generated no revenue from product sales, placing its program at a development stage that depends on clinical and regulatory progress before any commercial sales. This background shows that the offering is taking place while the company is still developing its lead candidate, rather than after bringing an approved treatment to market.
In the ASPIRO trial, 15 patients had received doses as of the August 18, 2026, data cutoff, and the company reported 72 treatment-emergent adverse events among patients who received doses. Aspen describes the Phase 1/2a trial as open-label, with no placebo or control group. It also cautioned that results from this type of trial may not predict the results of a later controlled trial. The company said the measures of clinically meaningful change used in the trial had not been discussed with the Food and Drug Administration or any other government regulatory agency, and had not been independently verified by an external party. The reported figures therefore remain tied to the existing trial data and the limitations the company included in its prospectus.
Aspen says the FDA granted sasineprocel Regenerative Medicine Advanced Therapy designation for levodopa-responsive Parkinson’s disease and Fast Track designation to improve motor function in patients with Parkinson’s disease. The company said, however, that the designations do not guarantee accelerated development, review or approval, and do not increase the likelihood of regulatory approval. Meanwhile, after receiving FDA feedback, the company expects to begin dosing in a Phase 3 trial during the second half of 2027. The start of that phase remains dependent on agency feedback, according to the prospectus, while the current ASPIRO trial remains open-label and without a control group.
On funding, Aspen reported $72.4 million in cash, cash equivalents and marketable securities as of June 30, 2026. It said, however, that based on its current operating plan, its resources at that date would not be sufficient to cover operating and capital expenditures for the 12 months following the issuance of the unaudited financial statements. The company cited substantial doubt about its ability to continue as a going concern. The prospectus also estimated adjusted pro forma net tangible book value after the offering at about $7.64 per share, based on an assumed offering price of $16 per share, which the company used in its dilution calculation. That assumption is not an announcement of the offering’s final price, which remained within a range of $15 to $17 in the prospectus.
For upcoming milestones, Aspen expects to begin dosing in a Phase 3 trial during the second half of 2027 after FDA feedback, then report additional long-term follow-up data from the ASPIRO trial in the first half of 2028. These two dates set out the timeline the company gave for its clinical program: the expected move to a Phase 3 trial first, followed by an update on follow-up data. The dates are expectations stated in the prospectus, not confirmed completion dates. The October 26 document describes the offering and price as preliminary and provides no evidence of a final share price or the start of trading.